Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Olema"


5 mentions found


Here are Tuesday's biggest calls on Wall Street: Oppenheimer reiterates Nvidia as outperform Oppenheimer said it's sticking with its outperform rating on shares of Nvidia. Citi reiterates Eli Lilly as buy Citi said the biopharma company is "riding the GLP-1 rocket." Citi downgrades Clorox to neutral from buy Citi said that the bullish thesis for the stock has largely played out for now. Citi upgrades Estee Lauder to buy from neutral Citi said it sees a "topline inflection point" for the stock. Barclays upgrades Array Technologies to overweight from equal weight Barclays said it sees share gains for the solar company.
Persons: Oppenheimer, McCormick, Argus, Needham, it's, Nelson Peltz, Melius, Horton, Citi, Eli Lilly, Estee Lauder, ARRY, JMP, Piper Sandler, Piper, Nio, CFRA, Goldman Sachs, Goldman, Blackstone, Petco Organizations: Nvidia, JPMorgan, Disney, Boeing, Citi, Coca, MTH, RBC, GE Vernova, General Electric, Bank of America, Meta, Travel, Barclays, Eaton, MI, Olema Pharmaceuticals, UBS, Bank of, of America Locations: underperform, LEN, DHI, Asia, Eaton, 4Q23
Olema Oncology could be a standout player in developing therapies for women's cancers, particularly in breast cancer, according to Citi Research. The stock was flat in trading on Tuesday, but has fallen more than 16% so far this year. Last year, Olema shares soared more than 470% as the company released a series of positive updates, particularly about its lead investigational oncology drug palazestrant , Nochomovitz said. "We believe palazestrant has emerged as a highly promising CERAN/SERD with opportunities across multiple lines of ER+ breast cancer," Nochomovitz wrote in a Tuesday note. CDK4/6 inhibitors are drugs that are used to treat metastatic breast cancer, or advanced stage IV breast cancer, which has spread to other organs in the body far from the breast.
Persons: Yigal Nochomovitz, Olema, Nochomovitz, Palazestrant, palazestrant, ribociclib Organizations: Oncology, Citi Research, FDA
JPMorgan initiates Light & Wonder as outperform JPMorgan initiated the Australian gambling company with an overweight and said it has earnings momentum. Evercore ISI reiterates Meta as outperform Evercore said it's bullish on Meta heading into earnings later this week. " Evercore ISI reiterates Amazon as outperform Evercore said it's bullish heading into Amazon earnings later this week. We are upgrading Bank of America (BAC) to OW from EW, upgrading Citigroup (C) to OW from UW, upgrading Goldman Sachs (GS) to OW from EW, and upgrading BNY Mellon (BK) to EW from UW. Bank of America reiterates Uber as buy Bank of America raised its price target on the stock to $73 per share from $68.
Persons: Oppenheimer, Raymond James, CrowdStrike, Mizuho, Evercore, it's, Morgan Stanley, Instacart, Morgan, Goldman Sachs, Raymond James downgrades, McDonald's, Wells, Baird, Tesla, TSLA, BTIG, Jefferies, Masimo, MASI, Uber Organizations: Accenture, Mizuho, JPMorgan, Morgan Stanley, Bank of America, Citi, Citigroup, BNY Mellon, BK, UW, Trust, AMD, Salesforce Inc, UBS, Spotify, sss, Western Alliance, WAL, Boeing, Olema Oncology, Breast Cancer, " Bank of America, Netflix, Seaport Locations: OW, UW, Wells Fargo
To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF. Potential upside to average price target of more than 40%. Four stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics . Another three stocks in the screen drew 100% buy ratings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals . Of these three, Rocket Pharmaceuticals got the highest potential upside of 81.4%.
Persons: Marinus, Biomea Organizations: Citi, Federal Reserve, CNBC Pro, Biotechnology, P Biotech ETF, Marinus Pharmaceuticals, Olema Pharmaceuticals, Ovid Therapeutics, Rocket Pharmaceuticals
"Enemy forces had a degree of success in their actions aimed at storming the city of Bakhmut," the General Staff of the Ukrainian Armed Forces said in its regular nighttime report. Russian officials say their forces are still capturing ground in street-by-street fighting inside Bakhmut. [1/5] A tank is towed through a road, amid Russia's invasion of Ukraine, near the bombed-out eastern Ukrainian city of Bakhmut, in the eastern Donetsk region, Ukraine, March 29, 2023. Russian forces shelled towns in central Zaporizhzhia region, including the contested centre of Hulyaipole, the Ukrainian general staff statement said. Rocket and artillery in the past 24 hours struck two areas of concentration of Russian forces, an ammunition depot and two fuel depots, it said.
Total: 5